Exicure to Present Poster at AAN 2019
Session Date/Times: Sunday, May 5, 2019 from 11:30 a.m. to 6:30 p.m. ET
Presentation number: 6-032
Poster session 1: Child Neurology: Neurogenetics poster grouping within Poster Neighborhood Number 6
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. We believe Exicure's proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure's lead program is in a Phase1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL. www.exicuretx.com
Source: Exicure, Inc.